• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
【24h】

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment

机译：脑脊髓液生物标志物在轻度认知障碍中诊断前驱性阿尔茨海默氏病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomarkers to identify prodromal AD and very early stage of AD dementia. We aimed to identify the cutoff values of cerebrospinal fluid (CSF) biomarkers for detecting prodromal AD. Methods: We assessed 56 patients with amnestic mild cognitive impairment (aMCI) who underwent lumbar puncture. Additionally, 87 healthy elderly individuals and 34 patients with AD dementia served as controls. Positron emission tomography was performed using florbetaben as a probe. We analyzed the concentration of Aβ1–42, total tau protein (t-Tau), and tau protein phosphorylated at threonine 181 (p-Tau181) in CSF with INNOTEST enzyme-linked immunosorbent assay. Results: For the detection of prodromal AD in patients with aMCI, the cutoff values of CSF Aβ1–42, t-Tau, and p-Tau181 were 749.5 pg/mL, 225.6 pg/mL, and 43.5 pg/mL, respectively. To discriminate prodromal AD in patients with aMCI, the t-Tau/Aβ1–42 and -p-Tau181/Aβ1–42 ratios defined cutoff values at 0.298 and 0.059, respectively. Conclusions: CSF biomarkers are very useful tools for the differential diagnosis of prodromal AD in aMCI patients. The concentration of CSF biomarkers is well correlated with the stages of the AD spectrum.
机译：背景/目的：阿尔茨海默氏病（AD）的疾病改良疗法已导致需要生物标志物来鉴定前驱性AD和AD痴呆的早期。我们旨在确定脑脊液（CSF）生物标志物的临界值，以检测前驱性AD。方法：我们评估了56例接受腰穿的轻度遗忘性轻度认知障碍（aMCI）患者。另外，将87名健康的老年人和34名AD痴呆患者作为对照。使用florbetaben作为探针进行正电子发射断层扫描。我们用INNOTEST酶联免疫吸附试验分析了CSF中苏氨酸181（p-Tau181）磷酸化的Aβ1-42，总tau蛋白（t-Tau）和tau蛋白的浓度。结果：为检测aMCI患者的前驱性AD，CSFAβ1-42，t-Tau和p-Tau181的截断值分别为749.5 pg / mL，225.6 pg / mL和43.5 pg / mL。为了区分aMCI患者的前驱性AD，t-Tau /Aβ1-42和-p-Tau181 /Aβ1-42的比值分别定义为0.298和0.059。结论：脑脊液生物标志物是鉴别aMCI患者前驱性AD的非常有用的工具。脑脊液生物标志物的浓度与AD谱图的阶段具有很好的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号